US Patent US10555556B2 declared invalid in infringement case

Sep.21.2022
US Patent US10555556B2 declared invalid in infringement case
Philip Morris lost patent infringement case in the US and its patent was invalidated, impacting e-cigarette product development.

Recently, in Case No.1:20-cv-0039-LO-TCB, Phimosis International accused R.J. Reynolds of patent infringement with No.US10555556B2, but the patent has since been invalidated in the U.S. after a lengthy legal battle that ended in Phimosis International's defeat. What does this ruling mean for the development of domestic electronic cigarette products?


Author bio: Lawyer Tang Shunliang is a specialized attorney in the field of new tobacco at the Beijing Zhong Lun Wen De Kunming law firm.


Part 1: Case Review


In case number 1:20-cv-0039-LO-TCB, R.J. Reynolds has brought a lawsuit against Phimow International for copyright infringement. Phimow International has responded by countersuing R.J. Reynolds for a series of patent infringement cases, highlighting the intense nature of the patent litigation between these two parties.


The case identifier is 1:20-cv-0039-LO-TCB.


On June 15, 2022, the Eastern District Court of Virginia ruled that R.J. Reynolds had infringed on two electronic cigarette technology patents owned by Philip Morris, identified as No. US9814265 and No. US10104911. As a result, they were ordered to pay $10.76 million in damages.


In this case, Phemo International has presented several weapons in its charge of infringement, including the patent No. US10555556B2, and has provided extensive evidence and reasoning to accuse VUSE VIBE of continuous infringement since June 29, 2022, specifically violating the first right claim of the patent. If this charge is proven, the compensation amount will not be limited to 10.76 million.


The R.J. Reynolds company has responded by stating that the patent should not have been granted. This is why there is now news of the recent invalidation of the patent.


Phimo International files a counter lawsuit against R.J. Reynolds for patent infringement of No.US10555556B2.


In its lawsuit, Philip Morris International compared its product VUSE VIBE to the patent No.US10555556B2 and argued that VUSE VIBE falls within the protection scope of "claim 1". However, the lawsuit fails to provide a comparison of whether VUSE VIBE contains the "first and second capillary" related technical features. Even if the patent is not found to be "invalid", it may still not constitute infringement (interested readers can download and read the legal documents).


Previously, Philip Morris International launched a patent lawsuit against British American Tobacco in Germany using patent "EP2282649," which is similar to a capillary oil guide. The court ruled in favor of British American Tobacco, stating that there was no infringement, resulting in Philip Morris International losing the case.


What is the technology solution protected by Claim 1 of patent No.US10555556B2?


A cylinder (commonly known as an e-cigarette) used in an aerosol generation system comprises a liquid storage portion that includes a pod container to maintain the liquid aerosol formation matrix. The pod container has an opening and at least two fluidly connected components (oil guiding components) form the liquid storage portion. All e-liquids need a corresponding storage component.


The first component of the liquid storage section includes:


The first capillary material, including various oil-conducting materials, fiber such as cotton, porous materials like ceramics, is used to evenly distribute the heat generating element for the e-cigarette. It is located near the opening of the shell. The second capillary material comes into contact with the first material and is separated from the opening by the first material (and does not come into contact with the heating sheet). Additionally, the second component of the liquid storage portion includes:


This refers to a device that utilizes an aerosol-forming matrix (e-liquid) to maintain a liquid state and supply the resulting aerosol-forming matrix to a container (e-liquid reservoir) made of a second capillary material. The device includes a fluid-permeable heating element (e-liquid permeator) that extends over the opening of the shell and the average pore size or porosity of the first capillary material is smaller than that of the second capillary material.


The key issue addressed by this patent is:


By setting up two guiding capillaries, the e-liquid is evenly distributed and atomized in the heater, ensuring no waste or reductions in e-liquid due to a decrease in volume or change in angle. This guarantees a high-quality vaping experience with every puff.


2.2 Common oil leakage issues have been resolved. However, the corresponding Mesh products still suffer from oil leakage problems.


The key technology of this plan is:


The use of two different types of oil-conducting materials achieves an even distribution of e-liquid to the heating element according to the frequency of vaping, resulting in improved vaporization efficiency. Claim 1 is not limited to a specific structural form and various forms and materials of oil-conducting materials and heaters are given as examples, making the scope of the invention broad. The technical solution provided in the manual is worth studying and learning from, and perhaps even finding better improvements. To aid readers in analysis, the figures have been marked by the author.


Figure 1 shows the overall technical plan, taking reference from Mesh and IQOS VEEV e-cigarettes. The core principle of oil storage, oil delivery and atomization is presented in Figure 2. Figure 3 illustrates the axial flow of oil passing through the heater and being uniformly released as smoke through the porous ceramic. Figure 4 demonstrates the radial oil delivery system (similar to traditional cotton core + metal wire) for atomization.


Closing Remarks


The ongoing patent wars between two tobacco giants indicate that both HNB and electronic vaporizer companies may continue to face legal challenges. It is possible that tobacco corporations have not yet turned their attention to Chinese electronic cigarette manufacturers, possibly due to other priorities.


However, their weapons arsenal is indeed very extensive, their research and development speed is very fast, and they are constantly laying out new patents.


Attachment 1: Global Distribution of Patents in the Same Cluster


Attachment 2: Patent Texts from Various Countries


Attachment 3: US Patent and Trademark Office invalidity decision.


Statement:


1. This article is intended for internal research and communication within the industry. It does not provide any investment or brand recommendations. This article should not be used as the basis for any investments. 2. The data and analysis conclusions mentioned in this article have not been confirmed in writing with the companies involved. Therefore, all information should be verified with official company releases.


This article is an original creation of 2FIRSTS Technology Co. Ltd. in Shenzhen. The copyright and usage rights belong to the company and no individual or organization is allowed to use, reproduce or copy the content for commercial purposes without authorization. Any infringement of the company's copyright will be subject to legal action.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal is among the countries opposing the UK Tobacco and Vapes Bill, which would ban tobacco sales to people born on or after Jan. 1, 2009. According to the report, Portugal, Croatia, the Czech Republic, Greece, Italy, Slovakia and Romania have submitted reasoned opinions and formal observations to Brussels, arguing that the bill breaches post-Brexit arrangements including the Windsor Framework.
Apr.24 by 2FIRSTS.ai
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands has outlined what the newly approved UK Tobacco and Vapes Act 2026 means for retailers. The legislation received Royal Assent on April 29, 2026, and gives the Government powers to extend tobacco-style regulation to a wider range of products, including vaping products, heated tobacco, nicotine pouches and cigarette papers. Imperial Brands emphasized that most measures will be introduced in phases rather than taking effect immediately.
May.11 by 2FIRSTS.ai
Tasmanian Lower House Passes Tougher Tobacco Bill With Higher Penalties for Sales to Minors
Tasmanian Lower House Passes Tougher Tobacco Bill With Higher Penalties for Sales to Minors
The Tasmanian House of Assembly has passed a new bill aimed at cracking down on the sale of smoking products to children and curbing the illicit tobacco trade. Under the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026, businesses caught selling tobacco products to minors would face steeper, tiered fines.
Apr.23 by 2FIRSTS.ai
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13